Fludarabine (NSC 118218)

For research use only.

Catalog No.S1491 Synonyms: FaraA, Fludarabinum

103 publications

Fludarabine (NSC 118218) Chemical Structure

CAS No. 21679-14-1

Fludarabine (NSC 118218, FaraA, Fludarabinum) is a STAT1 activation inhibitor which causes a specific depletion of STAT1 protein (and mRNA) but not of other STATs. Also a DNA synthesis inhibitor in vascular smooth muscle cells. Fludarabine induces apoptosis.

Size Price Stock Quantity  
10mM (1mL in DMSO) EUR 123 In stock
EUR 95 In stock
EUR 304 In stock
EUR 461 In stock
EUR 874 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Fludarabine (NSC 118218) has been cited by 103 publications

Purity & Quality Control

Choose Selective STAT Inhibitors

Biological Activity

Description Fludarabine (NSC 118218, FaraA, Fludarabinum) is a STAT1 activation inhibitor which causes a specific depletion of STAT1 protein (and mRNA) but not of other STATs. Also a DNA synthesis inhibitor in vascular smooth muscle cells. Fludarabine induces apoptosis.
Targets
STAT1 [4]
(Vascular smooth muscle cells)
In vitro

Fludarabine efficiently inhibits the proliferation of RPMI 8226 cells with IC50 of 1.54 μg/mL. The IC50 of Fludarabine against MM.1S and MM.1R cells is 13.48 μg/mL and 33.79 μg/mL, respectively. In contrast, U266 cells are resistant to Fludarabine with IC50 of 222.2 μg/mL. Fludarabine treatment results in increased number of cells in the G1 phase of cell cycle, accompanied with a concomitant reduction of cells at the S phase of cell cycle in a time-dependent manner. Fludarabine induces a cell cycle block and triggers apoptosis in MM cells. Fludarabine triggers time-dependent cleavage of caspase-8, -9, and -3, -7, followed by PARP cleavage. Fludarabine increases expression of Bax in a time-dependent fashion, while the expression of Bak doesn't change. After exposure to Fludarabine for 12 hours, RPMI 8226 cells shows a loss of membrane potential with 61.05% of the cells expressing low fluorescence of rhodamine 123 compared with 8.62% of cells in untreated control. [1] To enhance solubility, Fludarabine is formulated as the monophosphate (F-ara-AMP, fudarabine), which is instantaneously and quantitatively dephosphorylated to the parent nucleoside upon intravenous infusion. Inside the cells rephosphorylation occurs which leads to fuoroadenine arabinoside triphosphate (F-ara-ATP), the major cytotoxic metabolite of F-ara-A. [2] Fludarabine can also induce pro-inflammatory stimulation of monocytic cells, as evaluated by increased expression of ICAM-1 and IL-8 release. [3] Fludarabine does not affect the growth of ovarian cancer cell lines, whereas it induces marked and dose-dependent inhibition of proliferation in melanoma cell lines. [4] Fludarabine induces significant reduction of STAT-1 phosphorylation, whereas it does not change JAK2 activation. Interestingly, Fludarabine does not significantly affect the phosphorylation of these three STAT proteins. Fludarabine (1.5 mg) significantly prevents STAT-1 phosphorylation and also reduces the increased amount of this protein. No significant changes are demonstrated in JAK2 phosphorylation at 2 days, but Fludarabine inhibits JAK2-increased expression at 7 days. Fludarabine specifically inhibits STAT-1 activation without affecting other STAT proteins and consequently diminishes VSMC proliferation. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Jeko-1  MXLGeY5kfGmxbjDBd5NigQ>? MnPYNlAh|ryP MWiyOEBp NEf2d|NqdmirYnn0d{BmgHC{ZYPzbY9vKG:oIFnEUy=> NIW4N3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm0NFcyOid-MkW5OFA4OTJ:L3G+
MV-4-11 NIPPN2NCeG:ydH;zbZMhSXO|YYm= NVvLRpg3Oi53IN88US=> M3;EN|Q5KGh? NVP5SINncW6mdXPld{BieG:ydH;zbZMhe2yrZ3j0cJk> M3\leVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUGxOVg{Lz5{NUGxNVU5OzxxYU6=
THP-1 MlTFRZBweHSxc3nzJGF{e2G7 MmPtNk42KM7:TR?= NWfCV|d6PDhiaB?= NUjjfXdLcW6mdXPld{BieG:ydH;zbZMhe2yrZ3j0cJk> MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTFzMUW4N{c,OjVzMUG1PFM9N2F-
MOLM 13 MoO4RZBweHSxc3nzJGF{e2G7 NWXpN5EzOi53IN88US=> M3XodFQ5KGh? NFvGZlFqdmS3Y3XzJIFxd3C2b4Ppd{B{dGmpaITsfS=> M17nbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUGxOVg{Lz5{NUGxNVU5OzxxYU6=
KBM3/Bu2506 M4f2XWFxd3C2b4Ppd{BCe3OjeR?= MmfXNk42KM7:TR?= Mn;6OFghcA>? MkjVbY5lfWOnczDhdI9xfG:|aYOgd4xq\2i2bIm= NEX4ZZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGxNVU5Oyd-MkWxNVE2QDN:L3G+
Nalm-6 NE\VT2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\zZWJKSzVyPUG4JO69VQ>? MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB4MUGwNUc,OjVyNkGxNFE9N2F-
Reh NYD0ZpF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIi0RYdKSzVyPUOwJO69VQ>? MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB4MUGwNUc,OjVyNkGxNFE9N2F-
U2937 NWqzNVViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIL2TIZKSzVyPUG2JO69VQ>? NHToTIM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC2NVExOSd-MkWwOlEyODF:L3G+
Mec-1 M4nK[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|Ux97zgNUCwJO69VQ>? NHL6dYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC2NVExOSd-MkWwOlEyODF:L3G+
RPMI-8226 NYX2S4JDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXz5RlJpUUN3ME21NFAh|ryP NED6b2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC2NVExOSd-MkWwOlEyODF:L3G+
Molt-4 NVrzcIJjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWKzTG5IUUN3ME2xPFAh|ryP MofUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNkGxNFEoRjJ3ME[xNVAyRC:jPh?=
Nalm-6-FluR NHLlNFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jTUWlEPTB;MkWwJO69VQ>? MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB4MUGwNUc,OjVyNkGxNFE9N2F-
Raji  NGXHfnBHfW6ldHnvckBCe3OjeR?= M3XqUVPDqM7:TR?= NXSx[pBrOjRxNEivO|IhcA>? NIPSTHlqdmS3Y3XzJIFk[3WvdXzheIlwdnNib3[gdFU{NCCyNkOgZY5lKHB5M9Mg MnLuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NEC2PVUoRjJ2OUSwOlk2RC:jPh?=
PBMC M1nSPGZ2dmO2aX;uJGF{e2G7 M{XCTFUxNzFyMDFOwG0> NGK2R2IzPCCq MV;EUXNQ NH;aRnZqdmirYnn0d{BUXEGWMTDwbI9{eGixconsZZRqd25? NHPBN4o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmxNVg4Oid-MkS5NVE5PzJ:L3G+
MDA-231 Mn7SSpVv[3Srb36gRZN{[Xl? MWGxNFAh|ryP MX[yOEBp MVjEUXNQ M2TJNoRm[3KnYYPld{BKTE9iZYjwdoV{e2mxbh?= MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlzMUi3Nkc,OjR7MUG4O|I9N2F-
624.38mel  M1n5b2Z2dmO2aX;uJGF{e2G7 NX74epRrPTBizszN MUeyOEBp MVfEUXNQ Ml73[IVkemWjc3XzJGlFVyCneIDy[ZN{cW:w MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlzMUi3Nkc,OjR7MUG4O|I9N2F-
MDA-231 M{HUWWZ2dmO2aX;uJGF{e2G7 NX\TUHZvPTBvMkCwJO69VQ>? MlTWNlQhcA>? MkH2SG1UVw>? MULpcohq[mm2czDJSG8h[WO2aY\peJkhcW6mZYDlcoRmdnSueTDv[kBuWk6DIHzleoVtew>? M1SyVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUGxPFczLz5{NEmxNVg4OjxxYU6=
624.38mel  NXLLOm02TnWwY4Tpc44hSXO|YYm= NUPFT3FDPTBvMkCwJO69VQ>? M1;ablI1KGh? MWDEUXNQ MkPJbY5pcWKrdIOgTWRQKGGldHn2bZR6KGmwZHXw[Y5l\W62bImgc4YhdVKQQTDs[ZZmdHN? MnjoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MUG4O|IoRjJ2OUGxPFczRC:jPh?=
HMECs NVTSN4d[TnWwY4Tpc44hSXO|YYm= MnvzNVAxyqEQvF5CpC=> Ml3wN|bDqGh? MoDGbY5pcWKrdIOgTWZP|rQEoHHu[EBNWFNiaX7keYNm\CCVVFHUNUBxcG:|cHjvdplt[XSrb36gZY5lKEmURkGg[ZhxemW|c3nvci=> M1LVT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkGxN|I4Lz5{NEKxNVMzPzxxYU6=
HMECs  MVjGeY5kfGmxbjDBd5NigQ>? MmPGNVAxyqEQvF5CpC=> MnLlN|bDqGh? NV\jR4NbcW6qaXLpeJMhUU[QzsJCpI1m\GmjdHXkJJBpd3OyaH;yfYxifGmxbjDv[kBUXEGWMTDhcoQhW1SDVEOsJIJ2fCCwb4Sgc4YhW1SDVEK= M3LXN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkGxN|I4Lz5{NEKxNVMzPzxxYU6=
BJAB NHn2e5lCeG:ydH;zbZMhSXO|YYm= M4\CTFXDqM7:TR?= MVeyOEBp MnPnbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB3N{G0O{c,OjRyNUexOFc9N2F-
I-83 M3PaRWFxd3C2b4Ppd{BCe3OjeR?= MUG1xsDPxE1? MV:yOEBp MoTwbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NEPneHE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC1O|E1Pyd-MkSwOVcyPDd:L3G+
NALM6 NYC1cINCSXCxcITvd4l{KEG|c3H5 M17tfVXDqM7:TR?= NIDld2szPCCq MkTIbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? M37ae|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEW3NVQ4Lz5{NEC1O|E1PzxxYU6=
DU-145 M37neGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3i3fVAuOTBizsznM41t M3T0VFQ5KGkEoB?= NWT5PYFCcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd|NEixOUc,OjN5M{S4NVU9N2F-
Nalm-6 MmrXSpVv[3Srb36gRZN{[Xl? Mn3KNVDDqM7:TR?= MmG5NU8zNzRiaB?= M2ixPYlv\HWlZYOgZZV1d3CqYXf5 M2H1dVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkixNlI{Lz5{M{[4NVIzOzxxYU6=
Reh NHT5OW5HfW6ldHnvckBCe3OjeR?= MWexNOKh|ryP NH;tZVUyNzJxNDDo NEfKS3ZqdmS3Y3XzJIF2fG:yaHHnfS=> M1fzWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkixNlI{Lz5{M{[4NVIzOzxxYU6=
Nalm-6 NYjWOnZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEm4TY9KSzVyIPMIwFEx6oDLzszN MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ6MUKyN{c,OjN4OEGyNlM9N2F-
Reh M1XVbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxKOLKvEGw5qCK|ryP MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ6MUKyN{c,OjN4OEGyNlM9N2F-
HEC1A NEDiOIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYGxNFAuPTByIN88US=> MnzHNlQhcA>? Mnf0bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NVm5SnZpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1PVU3QTdpPkKzOVk2Pjl5PD;hQi=>
AN3CA MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYexNFAuPTByIN88US=> MUmyOEBp MojpbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M1z4W|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NUm1Olk4Lz5{M{W5OVY6PzxxYU6=
HEC50B MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGD2SlIyODBvNUCwJO69VQ>? MkXoNlQhcA>? MkX5bY5pcWKrdIOgZ4VtdCCpcn;3eIghe2yrZ3j0cJk> M4HT[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NUm1Olk4Lz5{M{W5OVY6PzxxYU6=
HEC1A M{nqTGFxd3C2b4Ppd{BCe3OjeR?= NHjRWnkzOC9zMECg{txO Mk\LNlQhcA>? MmGzbY5lfWOnczDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NXvuUVNtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1PVU3QTdpPkKzOVk2Pjl5PD;hQi=>
AN3CA MWXBdI9xfG:|aYOgRZN{[Xl? M1jBfFIxNzFyMDFOwG0> MVuyOEBp NGnSfmpqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV7NU[5O{c,OjN3OUW2PVc9N2F-
HEC50B NUPSTFQ{SXCxcITvd4l{KEG|c3H5 MUmyNE8yODBizszN NWHSb3ZKOjRiaB?= MWrpcoR2[2W|IHHwc5B1d3OrczDzcIlocHSueR?= MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV7NU[5O{c,OjN3OUW2PVc9N2F-
EHEB MojhRZBweHSxc3nzJGF{e2G7 M4LkXVQxKM7:TR?= MWSyOEBp NX;jb3ZCcW6mdXPld{BieG:ydH;zbZM> NFH6NZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S5O|A4PSd-MkO0PVcxPzV:L3G+
A549 MlfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\ZTWM2OD1zNT63xtEzNjhiwsXN MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN5N{G5Nkc,OjN|N{exPVI9N2F-
A549 GAPDH-deficient NYPoXnZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrsSld[UUN3ME2xPE42yrF{LkOgxtVO NUXkRXNLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzO|cyQTJpPkKzN|c4OTl{PD;hQi=>
CLL  NFfKTI9CeG:ydH;zbZMhSXO|YYm= NGrYUmcyOCEQvF5CpC=> M2HSd|I1NTl4IHi= MorobY5lfWOnczDhdI9xfG:2aXOgZ4VtdCCmZXH0bC=> NIHjSI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkKwO|Y5Pid-MkKyNFc3QDZ:L3G+
MEC1 NXn5cXQ6SXCxcITvd4l{KEG|c3H5 NFH3dHUyODEEoN88US=> NWPoSHlSPzJiaB?= MmLibY5lfWOnczDhdI9xfG:|aYOgd4lodmmoaXPhcpRtgQ>? NGfpTm49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkGzNlk4Oyd-MkKxN|I6PzN:L3G+
U937  MlK1RZBweHSxc3nzJGF{e2G7 MXywMlgh|ryP MWO0MVQ5KGh? MoXCbY5lfWOnczDhdI9xfG:|aYOgd4xq\2i2bIm= M3jU[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MEe0O|AxLz5{MkC3OFcxODxxYU6=
U937  Ml;GRZBweHSxc3nzJGF{e2G7 M3TqN|Eh|ryP NIHYN486PiCq NYPIcZVpcW6mdXPld{BieG:ydH;zbZMhe2yrZ3j0cJk> MmXQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJyMkO1NlMoRjJ{MEKzOVI{RC:jPh?=
Daudi M{HqV2Fxd3C2b4Ppd{BCe3OjeR?= M3PZdlIxKM7:TR?= MkPBPVYhcA>? NF3RVJVqdmS3Y3XzJIFxd3C2b4Ppd{B{dGmpaITsfS=> NHjKWm89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkCyN|UzOyd-MkKwNlM2OjN:L3G+
J45.01 M1i0Z2Fxd3C2b4Ppd{BCe3OjeR?= NV\YW2g{OSEQvF2= M3jHTlk3KGh? NHLEZmZqdmS3Y3XzJIFxd3C2b4Ppd{B{dGmpaITsfS=> NIH2WJo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkCyN|UzOyd-MkKwNlM2OjN:L3G+
RPMI 8226 MnXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17KUWlEPTB;MkWuPeKhyrIEoEOuO{DPxE1? MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl2OEK2OEc,OjF7NEiyOlQ9N2F-
CEM NV;FSoVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnKxTWM2OD1{LkVCpOKyyqByLkSg{txO MoX0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7NEiyOlQoRjJzOUS4NlY1RC:jPh?=
Raji MkDjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVL2[3ZGUUN3ME2wMlQ4yqEEsdMgNE4xPCEQvF2= MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl2OEK2OEc,OjF7NEiyOlQ9N2F-
U937 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\HUodHUUN3ME2wMlI1yqEEsdMgNE4xPCEQvF2= NY\vWI1PRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5OFgzPjRpPkKxPVQ5OjZ2PD;hQi=>
K562 NFzURpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTBwNEVCpOKyyqByLkC1JO69VQ>? MoHNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7NEiyOlQoRjJzOUS4NlY1RC:jPh?=
NALM-6 M4DX[GFxd3C2b4Ppd{BCe3OjeR?= MnjRNVAh|ryPwrC= NYfOUmlPOjRiaB?= NUOyb244cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDzcIlocHSueR?= MljFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF4OUmzPFMoRjJzNkm5N|g{RC:jPh?=
JMV-3 NUK0eYxTSXCxcITvd4l{KEG|c3H5 NInMPYwyOCEQvF5CpC=> MXSyOEBp NGDWOJBqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IIPsbYdpfGy7 MmH5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF4OUmzPFMoRjJzNkm5N|g{RC:jPh?=
EHEB MXHGeY5kfGmxbjDBd5NigQ>? MVi1MVUxKM7:TR?= NVG5S4xmOjRiaB?= MWfk[YNz\WG|ZYOgdFIyKGW6cILld5Nqd25ic3nncolncWOjboTsfS=> Mnm1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFzNkizPVEoRjJzMU[4N|kyRC:jPh?=
JVM-2  MU\GeY5kfGmxbjDBd5NigQ>? MVyzNEDPxE1? Mk\XNlQhcA>? M37wc4Rm[3KnYYPld{BxOjFiZYjwdoV{e2mxbh?= NH3N[5k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUG2PFM6OSd-MkGxOlg{QTF:L3G+
KBM3/Bu2506 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7kcGl1UUN{ME2wMlY4KML3TR?= M3vHPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyOUOzOVA6Lz5{MEmzN|UxQTxxYU6=
KBM3/Bu2506 Ml;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYSwMlYh|ryP MmXWNlQhcA>? NEH5VZpqdmO{ZXHz[ZMhfGinIHPlcIwh\nKjY4Tpc44hcW5iUz3wbIF{\Q>? MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODl|M{WwPUc,OjB7M{O1NFk9N2F-
MDA-MB-231 NFLWZ3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXmPIxKSzVyPUSuNEDPxE1? NILFepI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MES0O|M6OCd-MkC0OFc{QTB:L3G+
MCF-7 NFHPbm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnK4TWM2OD1zNT6wJO69VQ>? NGG0Vlc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MES0O|M6OCd-MkC0OFc{QTB:L3G+
HLE-B3  NGT4RnJHfW6ldHnvckBCe3OjeR?= NYq3S5pCOjVizszN NWriT44yPDhiaB?= M4jJd4Jtd2OtczDJSm4u|rQkgKPpcoR2[2WmIGPURXQyKHCqb4PwbI9zgWyjdHnvckBidmRiSVTPJIV5eHKnc4Ppc44> NFLFZlc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MESzOVE2QCd-MkC0N|UyPTh:L3G+
K562 MoO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\2cmc4OiCq NVnHPVdiUUN3ME2zMlMhdk1? NEGyVnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEOwO|E6QCd-MkCzNFcyQTh:L3G+
BW-225 M1rZR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13XXmlEOjB;MT6zO{DEnzFy4pkSPOKh|ryPwrC= MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDZ4MUO4NEc,OTh4NkGzPFA9N2F-
OH-65 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3joVmlEOjB;MT6zO{DEnzFy4pkSPOKh|ryPwrC= M2HzR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6Nk[xN|gxLz5zOE[2NVM5ODxxYU6=
GR-145 NUT3d3plT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|IxRTJwN{Sgx7chOTEkiKK4JEDPxE4EoB?= NFfOVG49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOE[2NVM5OCd-MUi2OlE{QDB:L3G+
A549 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TvbWlEOjB;NT60PEDEnyBzMPMIllgh|ryPwrC= M1;L[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6Nk[xN|gxLz5zOE[2NVM5ODxxYU6=
CaSki  NHr1OWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LkdGlEOjB;MT6zO{DEnyBzMPMIllch|ryPwrC= M2LpcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6Nk[xN|gxLz5zOE[2NVM5ODxxYU6=
ZMK-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|IxRTFwM{egx7chOTEkiKK2JO69VcLi NF;x[WI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOE[2NVM5OCd-MUi2OlE{QDB:L3G+
SKW6.4 NH;QVmxCeG:ydH;zbZMhSXO|YYm= M3zkcFAvODFvMUCg{txO MYiyOE81QCCq M2Hieolv\HWlZYOgZ4VtdCCmZXH0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLTDk[ZBmdmSnboSgcYFvdmW{ MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDB7MkO0NEc,OThyOUKzOFA9N2F-
RPMI 8226 NWDDR|FET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUGyOEBp NHnuPWlKSzVyPUGuOVTDqM7:TR?= NEDxRYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{m3OlE5Pid-MUe5O|YyQDZ:L3G+
MM.1S M4HMSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrRfXg1QCCq NXSwe|ZUUUN3ME2xN{41QMLizszN NUTFW3VFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe5O|YyQDZpPkG3PVc3OTh4PD;hQi=>
MM.1R M1\OT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fLOFQ5KGh? M{Pxe2lEPTB;M{OuO|kh|ryP NYPqNnI4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe5O|YyQDZpPkG3PVc3OTh4PD;hQi=>
U937 MorVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7aSoR5UUN3ME2zMFIxOCEEsTC1OlAhdk1? NWTGXpNFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUW5N|A{PjFpPkG1PVMxOzZzPD;hQi=>
CLL5 MYXBcpRqfHWvb4KgZZN{[Xl? MVS0PEBpenN? NH;2em1CdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBEVEx3IHPlcIx{KGm|b3zheIVlKG[{b32gR2xNKHCjdHnlcpQh[XO|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgOFghcHK|IHL5JGZCS1NiYX7hcJl{cXNuIFXDOVAhRSByLkG2JO69VS5? Mn\RQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4N{O3N|koRjJ2NkezO|M6RC:jPh?=
K562 MkHpR5l1d3SxeHnjbZR6KGG|c3H5 M4TY[FczKGi{cx?= Mlm3R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gdIFkdGm2YYjlcE1z\XOrc4ThcpQhUzV4MjDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOC5{NjFOwG0v NVnsfJB{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC2NFU3PTZpPkKwOlA2PjV4PD;hQi=>
CLL3 NY\NcY1iSW62aYT1cY9zKGG|c3H5 MXS0PEBpenN? M3G3UWFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JGNNVDNiY3XscJMhcXOxbHH0[YQh\nKxbTDDUGwheGG2aXXueEBie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBi\nSncjC0PEBpenNiYomgSmFEWyCjbnHsfZNqeyxiRVO1NEA:KDBwM{Wg{txONg>? NUT3NFAzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2O|M4OzlpPkK0Olc{PzN7PD;hQi=>
CLL4 MVPBcpRqfHWvb4KgZZN{[Xl? M{TVU|Q5KGi{cx?= MWjBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDDUGw1KGOnbHzzJIl{d2yjdHXkJIZzd21iQ1zMJJBifGmnboSgZZN{\XO|ZXSgZZMh[2WubDD2bYFjcWyrdImgZYZ1\XJiNEigbJJ{KGK7IF\BR3Mh[W6jbInzbZMtKEWFNUCgQUAxNjZ2IN88UU4> NX;FfGpsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2O|M4OzlpPkK0Olc{PzN7PD;hQi=>
CEM-DNR-B NGf1OYJEgXSxdH;4bYNqfHliYYPzZZk> M{LLWVczKGi{cx?= NG\YemdEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBETU1vRF7SMWIh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEGuNFEh|ryPLh?= NVnFZ5lURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC2NFU3PTZpPkKwOlA2PjV4PD;hQi=>
primary CLL M3yzSWN6fG:2b4jpZ4l1gSCjc4PhfS=> MXrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDwdolu[XK7IFPMUEBk\WyuczygUGQ2OCB;IEGuNUDPxE1w NIXIW2w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG0PFM6Oid-MkWxOFg{QTJ:L3G+
CLL6 MlLERY51cXS3bX;yJIF{e2G7 NHvMdXE1QCCqcoO= NGPK[2ZCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBEVEx4IHPlcIx{KGm|b3zheIVlKG[{b32gR2xNKHCjdHnlcpQh[XO|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgOFghcHK|IHL5JGZCS1NiYX7hcJl{cXNuIFXDOVAhRSBzLk[g{txONg>? M3nR[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkezO|M6Lz5{NE[3N|c{QTxxYU6=
CLL2 M{mzeWFvfGm2dX3vdkBie3OjeR?= Mm\iOFghcHK| NHjxcWFCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBEVEx{IHPlcIx{KGm|b3zheIVlKG[{b32gR2xNKHCjdHnlcpQh[XO|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgOFghcHK|IHL5JGZCS1NiYX7hcJl{cXNuIFXDOVAhRSB{Lk[2JO69VS5? MlfJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4N{O3N|koRjJ2NkezO|M6RC:jPh?=
HCT116 NIHTeYlEgXSxdH;4bYNqfHliYYPzZZk> NVfrbJJjPzJiaILz Ml;0R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGNVOTF4IHPlcIx{KGGodHXyJFczKGi{czDifUBUWkJiYYPzZZktKEmFNUCgQUA3NjZizszNMi=> NIrsbXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS2NlI4Pyd-MkW0OlIzPzd:L3G+
PBMC M1T2SmN6fG:2b4jpZ4l1gSCjc4PhfS=> NX;JN2dlPDhiaILz MVPDfZRwfG:6aXPpeJkh[WejaX7zeEBx[XSrZX70JHBDVUNiYX\0[ZIhPDhiaILzJIJ6KEOnbHzUbZRz\S2EbIXlJIF{e2G7IHnuJJBz\XOnbnOgc4YhdW:3c3WgUVIyOEJ2IHPlcIx{NCCLQ{WwJF0hOTBizszNMi=> NGH4[G49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW2NlQyPyd-MkW1OlI1OTd:L3G+
CHO MYTGeY5kfGmxbjDhd5NigQ>? NYjkc5NCSmmwZHnu[{Bi\m[rbnn0fUBl\XSncn3pcoVlKGK7IHTpd5Bt[WOnbXXueEBw\iC|cHXjbYZq[yCkaX7kbY5oKG:oIGuxNlVKZU5vKEStZY1qdm9vMz3pc4RweGinbnX0bJltMS2jZHXuc5NqdmViaX6gcYVu[nKjbnXzJI9nKEOKTzDj[YxteyC|dHHicJkhfHKjboPm[YN1\WRid3n0bEB1cGVicnH0JIFl\W6xc3nu[UBCOyC{ZXPldJRweixiS3mgQUAyOC52IN88UU4> MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek84PzB5M{KwK|44PzB5M{KwQE9iRg>?
JVM2 MnPaRY51cXS3bX;yJIF{e2G7 MUjBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDoeY1idiCMVl2yJINmdGy|IHHzd4V{e2WmIHHzJINmdGxidnnhZoltcXS7IHHmeIVzKDR6IHjyd{BjgSCIQVPTJIFv[Wy7c3nzMEBGSzVyIE2gNVAvPCEQvF2u MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ5M{ezPUc,OjR4N{O3N|k9N2F-
HeLa MkfnRY51cXS3bX;yJIF{e2G7 NWf4cFZkSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gTIVN[SClZXzsd{Bie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBjgSCPVGSgZZN{[XluIFXDOVAhRSBzNjFOwG0v NV\sNoQ4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2O|M4OzlpPkK0Olc{PzN7PD;hQi=>
CLL1 M1XxcGFvfGm2dX3vdkBie3OjeR?= MWe0PEBpenN? MnLqRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgR2xNOSClZXzsd{Bqe2:uYYTl[EBnem:vIFPMUEBx[XSrZX70JIF{e2W|c3XkJIF{KGOnbHygeoli[mmuaYT5JIFnfGW{IES4JIhzeyCkeTDGRWNUKGGwYXz5d4l{NCCHQ{WwJF0hOTdwMTFOwG0v NEnCXFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[3N|c{QSd-MkS2O|M4Ozl:L3G+
CEM NGHkVlNEgXSxdH;4bYNqfHliYYPzZZk> M37YcFczKGi{cx?= MULDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDDSW0h[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEG5MlQ6KM7:TT6= MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODZyNU[1Okc,OjB4MEW2OVY9N2F-
T47D NGXUW4VEgXSxdH;4bYNqfHliYYPzZZk> NFSxfmc4OiCqcoO= MVjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDUOFdFKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDTVmIh[XO|YYmsJGlEPTBiPTC0Ok4zKM7:TT6= M1LYVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NE[yNlc4Lz5{NUS2NlI4PzxxYU6=
A549 M2nIU2N6fG:2b4jpZ4l1gSCjc4PhfS=> MknjO|IhcHK| MoXIR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyIE2gOFcvPDRizszNMi=> MmDUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB4MEW2OVYoRjJyNkC1OlU3RC:jPh?=
CCRF-CEM M4n5fWZ2dmO2aX;uJIF{e2G7 NGLieGoyOCC3TR?= NF;q[pYyKHSxIE[wJI1qdnN? M1fmPGRzfWdidILhcpNxd3K2IHnuJIh2dWGwIFPDVmYuS0WPIHPlcIx{KGG|c3Xzd4VlKGG|IFXOWFEudWWmaXH0[YQhfXC2YXvlJIF1KDFyIIXNJIFnfGW{IEGgeI8hPjBibXnud{BjgSCuaYH1bYQhe2OrboTpcIxifGmxbjDjc5VvfGmwZzDhcoFtgXOrcx?= NWryOI1lRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzPFg4ODVpPkKzN|g5PzB3PD;hQi=>
TC32 NUG0N|dyeUiWUzDhd5NigQ>? NHHGfVlyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiVFOzNkBk\Wyucx?= Mn;1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
U-2 OS MYrxTHRUKGG|c3H5 MoLUdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFVvMjDPV{Bk\Wyucx?= NW\6UmMzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
A673 MYXxTHRUKGG|c3H5 NYTYSZdJeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFG2O|Mh[2WubIO= M2Lub|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
DAOY M{L0TpFJXFNiYYPzZZk> NUWxNoFDeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFTBU3kh[2WubIO= MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Saos-2 NYf2T2pqeUiWUzDhd5NigQ>? MkHydWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOjb4OtNkBk\Wyucx?= M4HJd|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-37 MYDxTHRUKGG|c3H5 NFTRUWlyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStN|ch[2WubIO= NXq2S442RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
RD M3fETJFJXFNiYYPzZZk> NYrMW3BIeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGLEJINmdGy| MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SK-N-SH Mor4dWhVWyCjc4PhfS=> NWfoXGJPeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPLMW4uW0hiY3XscJM> NWDJTVhCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
MG 63 (6-TG R) MoXydWhVWyCjc4PhfS=> MmDKdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE2JIE[zJEg3NVSJIGKpJINmdGy| M{CwTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-12 NVvJ[o1teUiWUzDhd5NigQ>? M4rjWZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2xNkBk\Wyucx?= MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
NB1643 Moq4dWhVWyCjc4PhfS=> NGn0OIRyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKxOlQ{KGOnbHzz NV;RN41ORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
OHS-50 NFPR[oJyUFSVIHHzd4F6 M37SO5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCRSGOtOVAh[2WubIO= MkD3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
BT-12 NEDmbnNyUFSVIHHzd4F6 MXTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDCWE0yOiClZXzsdy=> NGTzSZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
LAN-5 NWnSO49seUiWUzDhd5NigQ>? NIqxb3VyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBNSU5vNTDj[Yxtew>? M33aO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB-EBc1 NHX0NI1yUFSVIHHzd4F6 NGjFTmlyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBPSi2HQnOxJINmdGy| NXnuU4NlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-SH NHjSeGZyUFSVIHHzd4F6 NVW2b|hIeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhW0tvTj3TTEBk\Wyucx?= MmjsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Rh41 MnvpdWhVWyCjc4PhfS=> M3u3NpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaESxJINmdGy| MkLsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
A673 Mn;GdWhVWyCjc4PhfS=> Mn\adWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgRVY4OyClZXzsd{k> NIjGPIk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
BT-37 MkHndWhVWyCjc4PhfS=> NVjwU3JKeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhSlRvM{egZ4VtdHN? NF7aZ5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
MG 63 (6-TG R) M3vWVJFJXFNiYYPzZZk> NFjYR4xyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBOTyB4MzCoOk1VTyCUKTDj[Yxtew>? NGT2U4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Rh30 M3jJOZFJXFNiYYPzZZk> NGTFZmpyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBTcDNyIHPlcIx{ M4\ITVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
U-2 OS MUTxTHRUKGG|c3H5 NWjvN4NueUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhXS1{IF;TJINmdGy| MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
OHS-50 M4nTSpFJXFNiYYPzZZk> MYLxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDPTHMuPTBiY3XscJM> M1jWd|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-SH MUDxTHRUKGG|c3H5 NHj6bVNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCRcoToc4dwdmGuIEPEJJZq[WKrbHn0fUB{[3KnZX6g[o9zKFONLV6tV2gh[2WubIO= MmfnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
RD M2ewbZFJXFNiYYPzZZk> MV7xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDSSEBk\Wyucx?= NWjwSmRTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Daoy MWjxTHRUKGG|c3H5 M{\PZpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KE:{dHjv[49v[WxiM1Sgeoli[mmuaYT5JJNkemWnbjDmc5IhTGGxeTDj[Yxtew>? MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
TC32 NXHWWoFieUiWUzDhd5NigQ>? MXHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBQenSqb3fvcoFtKDOGIHPhd5Bie2Vic3Py[YVvKG[xcjDUR|MzKGOnbHzz NG\pPZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
TC32 NILHWnRyUFSVIHHzd4F6 MXzxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBQenSqb3fvcoFtKDOGII\pZYJqdGm2eTDzZ5Jm\W5iZn;yJHREOzJiY3XscJM> NWjYNI8yRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
MG 63 (6-TG R) M2D0d5FJXFNiYYPzZZk> MnHWdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohV3K2aH;nc45idCB|RDD2bYFjcWyrdImgd4Nz\WWwIH\vdkBOTyB4MzCoOk1VTyCUKTDj[Yxtew>? NHLt[5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SJ-GBM2 Moe1dWhVWyCjc4PhfS=> MYXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucx?= MkfRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC NVXodppSeUiWUzDhd5NigQ>? MVPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?= NYHsRYVERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB-EBc1 MVPxTHRUKGG|c3H5 NFm2WHpyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKtSWJkOSClZXzsdy=> NFX4U4o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
LAN-5 NU[5RmsyeUiWUzDhd5NigQ>? M1;sOZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCOQV6tOUBk\Wyucx?= M2TnT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh18 M2WySJFJXFNiYYPzZZk> M1fMbJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaEG4JINmdGy| NWfKTm9rRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB1643 NYCzeZhGeUiWUzDhd5NigQ>? NYD0b286eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhVkJzNkSzJINmdGy| MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SK-N-MC MljsdWhVWyCjc4PhfS=> M33nRZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHNMNU5vTVOgZ4VtdHN? Moe5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SJ-GBM2 MU\xTHRUKGG|c3H5 M3W3bpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHNLNUeETUKgZ4VtdHN? MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
TC32 MWTxTHRUKGG|c3H5 M4XpdJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHREOzJiY3XscJM> NHnSRYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Rh18 NYT3TGU1eUiWUzDhd5NigQ>? MlridWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgVogyQCClZXzsdy=> NGXkc4Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Saos-2 M2GyNpFJXFNiYYPzZZk> NVjK[HVTeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhW2Gxcz2yJINmdGy| NXW4UI93RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SJ-GBM2 NUW3RlZieUiWUzDhd5NigQ>? M1X6UpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KE:{dHjv[49v[WxiM1Sgeoli[mmuaYT5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucx?= MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
RD NFThNm1yUFSVIHHzd4F6 NUP0RlBjeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiT4L0bI9od26jbDCzSEB3cWGkaXzpeJkhe2O{ZXXuJIZweiCURDDj[Yxtew>? M2TYblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
procaspase-9 / procaspase-3; 

PubMed: 27223263     


Procaspase-9 and procaspase-3 were analyzed by Western blot in CLL cells from three patients after a 48 h-incubation in the absence or presence of 3 μM aphidicolin (APC) with or without fludarabine at 0.3 and 1 μM. β-Actin served as a loading control.

p-p53 / p53; 

PubMed: 27223263     


(A–B) CLL cells from 3 different patients were incubated for 24 h with fludarabine at the indicated concentrations in the absence or presence of 3 μM aphidicolin (APC). Phosphorylation of p53 at Ser-15 and total p53 were analyzed by Western blot. Data sho䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෋à鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒

STAT1; 

PubMed: 26677135     


Representative western blot analysis of STAT1 in RAW 264.7 cells treated with STAT1 inhibitor fludarabine (Flu) for 24 h.

27223263 26677135
Immunofluorescence
α-SMA / Vimentin; 

PubMed: 28322315     


FLU (50 μM) reduces the expression of α-SMA and Vimentin protein in primary mouse activated HSCs (Hepatic Stellate Cells).

28322315
Growth inhibition assay
Cell viability ; 

PubMed: 24956101     


CLL cells RPMI/0.1% FBS were cultured on 0.5% BSA or 150 nM MMP-9 for 1 h prior to adding the indicated concentrations of fludarabine (Fluda). After 48 h (Fluda) cell viability was determined by flow cytometry using FITC-Annexin V and PI.

24956101
In vivo Tumors treated with PBS grow rapidly to approx-imately 10-fold their initial volume in 25 day, whereas, the tumors in the Fludarabine at 40 mg/kg increase less than 5-fold. A significant antitumor effect of 40 mg/kg Fludarabine on RPMI8226 tumor growth is demonstrated. RPMI8226 tumors treated with 40 mg/kg Fludarabine at day 10 increase apoptotic nuclei. Fludarabine is effective in suppressing RPMI8226 myeloma xenografts in SCID mice. [1]

Protocol

Cell Research:

[1]

- Collapse
  • Cell lines: Dexamethasone-sensitive (MM.1S) and -resistant (MM.1R) human MM cell lines, RPMI8226 and U266 cell lines
  • Concentrations: 2 μg/mL
  • Incubation Time: 24 hours
  • Method:

    After treated with Fludarabine or control, dexamethasone-sensitive (MM.1S) and -resistant (MM.1R) human MM cell lines, RPMI8226 and U266 cell lines (5 × 105 cells) are washed twice in phosphate-buffered saline (PBS) and fixed with 70% ice-cold ethanol, then centrifuged and suspended in PBS containing 100 μg/mL RNase A. After incubated for 30 minutes at 37 ºC, samples are resuspended in 25 μg/mL propidium iodide. Flow cytometry is performed on a FACSCalibur automated system. Apoptosis is determined by Annexin V-FITC apoptosis detection kit, according to the manufacturer's instructions. For TUNEL (terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling) assay, cells are analyzed by flow cytometry using the in situ cell death detection kit.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: Severe combined immunodeficient (SCID) mice bearing RPMI 8226 cells
  • Dosages: 40 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 57 mg/mL (199.83 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5%DMSO+40%PEG300+5%Tween80+50%ddH2O
For best results, use promptly after mixing.
8 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 285.23
Formula

C10H12FN5O4

CAS No. 21679-14-1
Storage powder
in solvent
Synonyms FaraA, Fludarabinum
Smiles C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)CO)O)O)F)N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04526795 Not yet recruiting Drug: Cytarabine|Drug: Fludarabine|Drug: Pegcrisantaspase Blast Phase Chronic Myelogenous Leukemia BCR-ABL1 Positive|Recurrent Acute Biphenotypic Leukemia|Recurrent Acute Lymphoblastic Leukemia|Recurrent Acute Myeloid Leukemia|Recurrent Chronic Myelogenous Leukemia BCR-ABL1 Positive|Recurrent T-Cell Prolymphocytic Leukemia|Refractory Acute Biphenotypic Leukemia|Refractory Acute Lymphoblastic Leukemia|Refractory Acute Myeloid Leukemia|Refractory Chronic Myelogenous Leukemia BCR-ABL1 Positive|Refractory T-Cell Prolymphocytic Leukemia M.D. Anderson Cancer Center|National Cancer Institute (NCI) December 31 2020 Phase 1
NCT03832127 Not yet recruiting Drug: 18F-Fludarabine Myeloma Nantes University Hospital|Cyceron April 1 2019 Phase 1
NCT03696537 Active not recruiting Drug: Fludarabine|Radiation: Total Marrow Irradiation (TMI) Acute Myeloid Leukemia|Chronic Myeloid Leukemia|Acute Lymphocytic Leukemia|Myelodysplastic Syndromes Naoyuki G. Saito M.D. Ph.D.|Indiana University August 29 2018 Phase 1
NCT02718755 Withdrawn Drug: Fludarabine|Drug: Cytarabine|Drug: Erwinase Hematologic Malignancy M.D. Anderson Cancer Center|Jazz Pharmaceuticals May 2018 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    how to re-suspend and deliver the inhibitor for in vivo experiments?

  • Answer:

    For S1491, Fludarabine, we tested a vehicle: 30% Propylene glycol, 5% Tween 80, 65% D5W that you can resuspend the compound in at up to 30mg/ml. It's a suspension and can only be given via oral gavage.

STAT Signaling Pathway Map

Related STAT Products

Tags: buy Fludarabine (NSC 118218) | Fludarabine (NSC 118218) supplier | purchase Fludarabine (NSC 118218) | Fludarabine (NSC 118218) cost | Fludarabine (NSC 118218) manufacturer | order Fludarabine (NSC 118218) | Fludarabine (NSC 118218) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID